

```

>PpViperin-WT
MLMPLCFKDVHSSFFSALLRWILMMVSGTLVSLGMISRPKIRTREQKEASSAQVTPSSVNYHFTRQCNYKCGFCFHTAKTSFVLPIEEAKRGLRLLKEAG
MEKINFSGGEPFLHERGSFLGELVRYCKQELLLPSVISVNGSLIKESWFQKYGDYLDILAVSCDSFNEDTNKVIGRGQKKSHLDNLHKVCSWCRDYKV
AFKINSVINTYNVDEDMTEQITALNPVRWKVFQCCLLDGENAGENSIREAEKFVISEQQFQDFLDRHKS VKCLVPESNQKMRDS YLILDEYMRFLDCREG
RKDPSKSVLDVGVEEAIKFSGFDEKMFLIRGGKYVWSKEDMKLEW

>PpViperin-(-1)-(0)
MLMPLCFKDVHSSFFSALLRWILMMVSGTLVSLGMISRPKIRTREQKEASSDR*PLQAV*TTILPGSAITNVAFASTLRRPRSSCLLKQSEGYDF*KKQE
WKKSTFQVESPFPMREALFWESWSDTANRSCCFRASASLVMV*SKNPGFRNTVTTWTFQLAIVLTKTPIKSLAEVRARRAI*TICIKFVPGAGTTRW
LSKSTF*STPTMWTKI*QSRSL*TCAGRSSSV*LMVKT LGRTASARQKNLSLVSSNSKTSWTAIRASSVWFQSLIKR*ETLT*FLMNICASWIAERGG
KIRQSPFWMLVWKRPSSSSVLMRRCSS*EGGNMCGARKI*NWSG

>PpViperin-(-1)-(+1)
MLMPLCFKDVHSSFFSALLRWILMMVSGTLVSLGMISRPKIRTREQKEASSDR*PLQAV*TTILPGSAITNVAFASTLAKTSFVLPIEEAKRGLRLLKEAG
MEKINFSGGEPFLHERGSFLGELVRYCKQELLLPSVISVNGSLIKESWFQKYGDYLDILAVSCDSFNEDTNKVIGRGQKKSHLDNLHKVCSWCRDYKV
AFKINSVINTYNVDEDMTEQITALNPVRWKVFQCCLLDGENAGENSIREAEKFVISEQQFQDFLDRHKS VKCLVPESNQKMRDS YLILDEYMRFLDCREG
RKDPSKSVLDVGVEEAIKFSGFDEKMFLIRGGKYVWSKEDMKLEW

>PpViperin-(-2)-(+1)
MLMPLCFKDVHSSFFSALLRWILMMVSGTLVSLGMISRPKIRTREQKEASSADHSHKQCELPFYPAVQIQMWLLPLHLRRPRSSCLLKQSEGYDF*KKQE
WKKSTFQVESPFPMREALFWESWSDTANRSCCFRASASLVMV*SKNPGFRNTVTTWTFQLAIVLTKTPIKSLAEVRARRAI*TICIKFVPGAGTTRW
LSKSTF*STPTMWTKI*QSRSL*TCAGRSSSV*LMVKT LGRTASARQKNLSLVSSNSKTSWTAIRASSVWFQSLIKR*ETLT*FLMNICASWIAERGG
KIRQSPFWMLVWKRPSSSSVLMRRCSS*EGGNMCGARKI*NWSG

```

Additional file 2: Amino acid sequences corresponding to the mutated viperin sequences amplified from genomic DNA from WT EPC-EC and *viperin*^{-/-} EPC-EC-Viperin-C7 and -C11 and subcloned by TOPO TA cloning.

The first amino acids affected by a frameshift are in red, the frameshifts are in green and the premature end of the polypeptides are represented by a red star. The immunogen peptide recognized by the anti-viperin antibody (PA5-42231, Invitrogen) is outlined in black.